Month: September 2020

Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritisWell-tolerated with comparable safety profile to intravenous ertapenemSpero intends to complete NDA submission for U.S. regulatory approval of tebipenem HBr in the second quarter of 2021Management to host conference call and live webcast at 8:00 a.m. EDT todayCAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet medical need areas involving multidrug-resistant (MDR) bacterial infections and rare diseases, today announced positive topline results...

TORONTO, Sept. 08, 2020 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) is pleased to report drill results from recent exploration drilling at the Valentine Gold Project, central Newfoundland (the “Project”). These latest results represent fire assay data from thirteen drill holes completed within the six-kilometre long Sprite Corridor, including the new Berry Zone. Highlights include:VL-20-838 intersected 1.47 g/t Au over 111 metres, including 35.02 g/t Au over 1 metre and including 14.92 g/t Au over 2 metres;VL-20-839 intersected 14.39 g/t Au over 9 metres, including 60.13 g/t Au over 2 metres, and 4.25 g/t Au over 15 metres, including 13.34 g/t Au over 4 metres;VL-20-837 intersected 8.24 g/t Au over 5 metres, including 36.21 g/t Au over 1 metre; andVL-20-844 intersected 4.38 g/t Au over 8...

The Company’s National Roll-Out of Tauri-Gum™ Targets Many Thousands of Retail Locations in More Than 30 U.S. StatesNew York, NY, Sept. 08, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE —  Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today commenced its long awaited national launch of its flagship brand – Tauri-Gum™.  Comprised of six distinct flavors, Tauri-Gum™ is a fast growing, technologically advanced product line that delivers Cannabidiol (“CBD”) and Cannabigerol (“CBG”) – as a Supplement – to customers, in the form of a proprietary chewing gum...

TORONTO, Sept. 08, 2020 (GLOBE NEWSWIRE) — Cardinal Resources Limited (ASX / TSX: CDV) (“Cardinal” or “the Company”) refers to its announcements of 2 and 3 September 2020 in relation to the revised Nord Gold S.E. (“Nordgold”) on-market takeover offer for Cardinal at A$0.90 cash per share (“Nordgold Takeover Bid”).As announced earlier today, Cardinal has received a revised and improved proposal for an off-market takeover offer from Shandong Gold Mining (HongKong) Co., Ltd. (“Shandong Gold”), pursuant to which Shandong Gold will offer to acquire all of the shares in Cardinal it does not presently own at a cash price of A$1.00 per share (“Improved Shandong Gold Offer”).The Cardinal Board, together with the Special Committee and its financial and legal advisers, carefully considered the Improved Shandong Gold Offer in detail and given...

TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) — Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the first patient has been dosed in the Phase 1/2 clinical trial of NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.“The dosing of the first patient in this important study represents a significant milestone for Kitov,” said Bertrand Liang, M.D., Ph.D., Chief Medical Officer of Kitov. “Based on the encouraging pre-clinical data generated by NT219 as both monotherapy and in combination with several anti-cancer drugs, we believe that this promising drug candidate has the potential to...

OMER, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) — Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that it was informed by ScoutCam, Inc. (OTC: SCTC), Medigus’ subsidiary and a leading developer and manufacturer of customized visual solutions and supplementary technologies, that ScoutCam has been officially included on a Fortune 500 multinational healthcare corporation’s Approved Supplier List (ASL). The qualification will allow ScoutCam to develop, manufacture and supply a complete visualization solution for the global company’s minimally invasive surgical product, which incorporates ScoutCam’s single-use miniature video cameras.“We are extremely excited not only for the recognition of our superior technology, but...

Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapyUnprecedented improvement was observed in subjects on placebo added to background drug therapy, achieving median ACR CRISS score of 0.88784% of enrolled subjects were receiving background immunosuppressive drugs, reflecting recent trends in clinical practiceLenabasum treatment was safe and well-tolerated in this study with no new safety signals observedFurther analyses of data are underway, and results will be presented at upcoming medical conferencesLenabasum clinical trials in cystic fibrosis, dermatomyositis and systemic lupus erythematosus are ongoingCompany to host conference call and webcast today, September 8, 2020 at 8:30 a.m. ETNorwood, MA, Sept. 08, 2020 (GLOBE NEWSWIRE)...

NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) — Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present at the following upcoming virtual investor conferences.Dr. Alon Seri-Levy, Sol-Gel’s Chief Executive Officer, will provide an overview of the Company and give a business update.  A live webcast of the presentation will be available under the “Events and Presentations” in the investors section of the Company’s website at www.sol-gel.com. An archived webcast recording of the event will be available on the website for approximately 30 days.About Sol-Gel TechnologiesSol-Gel is a clinical-stage dermatology company focused...

NEWTOWN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the publication of an important, peer-reviewed study titled Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderate Traumatic Brain Injury. The study was published in the peer reviewed journal EMJ Radiology. 2020;1[1]:64-71.Traumatic brain injury (“TBI”) of varying severity can result in balance and movement disorders, for which the benefits of treatment with physical therapy has limits. In this study, a 9 patient subset of the original 43 patients published in “Translingual Neurostimulation for the Treatment...

GREENWICH, Conn., Sept. 08, 2020 (GLOBE NEWSWIRE) —  XPO Logistics, Inc. (NYSE: XPO), the largest provider of last mile logistics for heavy goods in North America, today announced the appointment of Erik Caldwell as president of its last mile business unit. Caldwell has P&L responsibility for XPO’s last mile operations in the US and Canada. The unit manages more than 10 million home deliveries and installations of big and bulky products annually, including appliances, exercise equipment and furniture.Caldwell has 16 years of executive experience with retail and industrial supply chains. He joined XPO in 2017 as chief operating officer, supply chain – Americas and Asia Pacific. Previously, Caldwell was senior vice president, supply chain and digital operations with Hudson’s Bay Company; senior vice president, global Rx...